Berenberg Bank Reiterates €108.00 Price Target for MorphoSys (MOR)

Share on StockTwits

Berenberg Bank set a €108.00 ($125.58) price target on MorphoSys (ETR:MOR) in a research note published on Friday. The firm currently has a neutral rating on the stock.

Other analysts have also recently issued research reports about the company. Oddo Bhf set a €110.00 ($127.91) price objective on MorphoSys and gave the company a buy rating in a research report on Friday, July 27th. JPMorgan Chase & Co. set a €100.00 ($116.28) price objective on MorphoSys and gave the company a buy rating in a research report on Thursday, May 17th. Commerzbank set a €98.00 ($113.95) price objective on MorphoSys and gave the company a buy rating in a research report on Thursday, July 19th. Independent Research set a €110.00 ($127.91) price objective on MorphoSys and gave the company a neutral rating in a research report on Friday, July 6th. Finally, Goldman Sachs Group set a €86.00 ($100.00) price target on MorphoSys and gave the stock a neutral rating in a research report on Thursday, May 24th. Two analysts have rated the stock with a sell rating, six have issued a hold rating and two have given a buy rating to the company. The stock presently has an average rating of Hold and an average target price of €96.00 ($111.63).

MorphoSys stock traded down €0.20 ($0.23) during mid-day trading on Friday, reaching €95.15 ($110.64). 204,151 shares of the stock traded hands, compared to its average volume of 153,687. MorphoSys has a 12-month low of €49.63 ($57.71) and a 12-month high of €88.10 ($102.44).

MorphoSys Company Profile

MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnership with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 drugs for the treatment of cancer, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.

See Also: Do Tariffs Work?

Analyst Recommendations for MorphoSys (ETR:MOR)

Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply